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1. Introduction 
Mycophenolic-acid (MPA) is a selective, non-competitive inhibitor of Inosine-
Monophosphate-Dyhydrogenase (IMPDH) leading to the inhibition of the de-novo 
synthesis of guanosine-nucleotides. In human lymphocytes inhibition of IMPDH results in 
altered cellular proliferation with arrest in the S-phase of the cell cycle. Due to the absence of 
a salvage pathway, proliferating activated t-cells are severely affected by the inhibitory 
effects of MPA (1-3). For patients after renal transplantation MPA is used either as 
mycophenolate-mofetil (MMF, Cellcept) or as enteric-coated mycophenolate-Sodium (EC-
MPS, Myfortic) in daily doses of 2000 mg respectively 1440 mg per day. 
Since its introduction in immunosuppressive therapy more than ten years ago, 
Mycophenolate-Mofetil (MMF) is an established part of immunosuppressive therapy after 
renal transplantation. Still in the first publication of the landmark Tricontinental trial 
because of possibly dose-related side effects of the drug (CMV-infection, gastrointestinal 
disturbances, and increased cancer risk) the need for individualization depending on clinical 
course or other factors was mentioned (4).  
The usefulness of pharmacokinetic measurements of MMF was shown in early studies 
stating that the Area-under the curve (AUC) of MMF is predictive of the likelihood of 
allograft rejection after renal transplantation in patients receiving mycophenolate mofetil (5). 
To facilitate therapeutic drug monitoring different limited sampling strategies for adult and 
pediatric patients after renal transplantation were established (6-13). 
The two available preparations of MPA (MMF, EC-MPS) showed equivalent drug exposure 
measured by MPA-AUC when applied to the patients in equimolar doses. Therefore, both 
preparations are seen as equipotent (14-16).  
2. Pharmacokinetics of MPA 
MPA trough levels show relevant inter- and intraindividual variability especially in patients 
with elevated serum creatinine and proteinuria (17-19). Clinically important, low trough  
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levels are associated with an increased frequency of rejection (20), whereas elevated MPA 
trough levels are related to an increased risk for infections (21). Nevertheless, relevant 
correlations between MPA trough levels and MPA-AUC values could not be detected, 
therefore the usefulness of measuring trough levels in routine care of renal transplant 
recipients is doubted (22-24). 
2.1 Effect of immunosuppressive therapy on MPA pharmacokinetics 
Concomitant immunosuppressive therapy has major influence on MPA pharmacokinetics. For 
patients on Cyclosporine (CsA)  therapy lower MPA trough levels are observed (25). In 
addition, MPA trough levels increased after discontinuation of CsA resulting in almost a 
doubling of MPA trough concentrations (26). In general, the variability of MPA-AUC in 
patients with concomitant cyclosporine and steroid therapy seems to be low (27). However, in 
154 patients with an immunosuppressive therapy consisting of CsA, prednisone and MMF the 
mean MPA AUC increased after 21 days although mean MMF dose was reduced (28).  
For patients treated with tacrolimus (TAC) increased MPA trough levels are reported (29). 
Additionally, a randomized trial with 150 participants, patients receiving TAC and MMF 
displayed significantly higher MPA trough levels and higher MPA exposure measured by 
MPA-AUC than those receiving CsA and the same dose of MMF. Equivalent MPA levels 
could only be attained in patients receiving CsA by increasing the MMF dose by 50% (30). 
Similar results were obtained for pediatric renal transplantation (31). Interestingly, at least in 
japanese renal transplant patients, a difference for MPA-AUC in patients with different 
tacrolimus-trough levels could not be detected (32). At least, for renal transplant recipients  
limited sample strategies for MPA-AUC with concomitant medication of tacrolimus are 
established (33). 
In patients with Sirolimus (SRL) MPA exposure in the presence of SRL is higher than MPA 
exposure with CsA. Therefore it was recommended, that the MMF dose should be reduced 
to 0.75 g twice a day in patients receiving SRL to obtain MPA-AUC levels comparable to that 
in patients treated with CsA and MMF 1 g twice a day (8). These results were confirmed in a 
pharmacokinetic study in 31 renal transplant patients (34). It was also shown, that although 
MPA peak concentration and time to peak concentration was comparable, the MPA-AUC 
was higher in patients receiving SRL instead of CsA (35).  
Steroids have been shown to induce the hepatic glucuronyltransferase (GT) expression 
enhancing the activity of uridine diphosphate-GT, the enzyme responsible for mycophenolic 
acid (MPA) metabolism. Therefore, also for steroids interactions with MPA are reported. 
During a steroid tapering and withdrawal phase in 26 patients MPA trough levels 
progressively increased and plasma MPA clearance declined (36). 
2.2 Effect of concomitant therapy on MPA pharmacokinetics 
For patients in the maintenance phase after transplantation it is known, that MPA-AUC 
increases with declining transplant function (37). This effect may be modulated by 
concomitant medication. Beside immunosuppression, patients after renal transplantation 
have to use antiviral prophylaxis. At least for Ganciclovir no effect on MPA clearance in 
kidney transplant recipients was reported (38).  
With respect to the use of proton pump inhibitors the published results are unequivocally. 
In japanese patients, the peak MPA-concentrations were lower with 30 mg lansoprazole 
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than with 10 mg rabeprazole or without PPI. For patients with cytochrome (CYP) 2C19, and 
multidrug resistance (MDR)1 C3435T polymorphisms this was also seen for the MPA-AUC  
(39). 
Patients after heart transplantation with PPI co-medication show significantly lower MPA 
plasma concentrations resulting in lower drug exposure exposing the patients at a higher 
risk for acute rejection (40). Also in patients with autoimmune diseases the co-medication of 
pantoprazole with MMF significantly influences the drug exposure and immunosuppressive 
potency of MMF (41). In contrast, the recently published sub-analysis of the CLEAR-study 
reported no difference in MPA-AUC in patients with or without PPI-therapy when a 3g/d 
loading dose of MMF for 5 days used. However, MPA concentrations   2 h and 12 h after 
MMF intake were reduced (42).  
At least for heart transplant recipients no influence of pantoprazole on EC-MPS 
pharmacokinetics could be disclosed (43). 
Own results in 74 patients in the early and maintenance phase after renal transplantation 
showed a relevant reduction in normalized MPA-AUC (40,9 +/- 19,7 vs. 26,1 +/- 11,7 
mg/l*h; p<0,01) in patients with PPI co-medication. A difference between patients using 
either omeprazole or pantoprazole in MPA-AUC could not be detected.  (Rath et al., 
Congress of the German Transplantation Society, 2009) 
3. Clinical relevance of MPA-AUC 
3.1 MPA-AUC and acute rejection 
In different clinical trials, MPA drug exposure was correlated with the occurrence of biopsy 
proven acute rejection (BPAR). In a double blind trial aiming for three predefined target 
MPA AUC values the incidence of BPAR was lower in patients with MPA AUC values 
between 30 and 60 µg x h/ml (28). Similar results were reported for a group of 46 stable 
patients after renal transplantation, with better graft function in patients with a MPA AUC > 
40 µg/ml*h and for pediatric renal transplantation (20;44;45).  
Three randomized trials, the OPTICEPT study, the APOMYGRE-trial (Adaption de 
Posologie du MMF en Greffe Renale) and the FDCC study (fixed-dose versus concentration 
controlled) investigated the benefit of therapeutic drug monitoring for MMF in renal 
transplant recipients.  
The APOMYGRE Trial was a study in 137 allograft recipients treated with basiliximab, 
cyclosporine A, corticosteroids and MMF. Patients were randomized to receive either 
concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA 
AUC based on three-point sampling was used to individualize MMF doses. At month 12, 
the concentration-controlled group had fewer treatment failures and acute rejection 
episodes. Therefore, the authors conclude, that therapeutic MPA monitoring using a limited 
sampling strategy can reduce the risk of treatment failure and acute rejection in renal 
allograft recipients 12 months post-transplant with no increase in adverse events (46). 
The FDCC study  was a randomized trial in 901 patients after renal transplantation allocating 
patients to receive MMF either in a fix dose or in a concentration controlled manner aiming at 
a predefined MPA AUC of 45 mg*h/L. In general, there was no difference in the incidence of 
primary treatment failure or biopsy proved rejection. However, MPA-AUC levels at day 3 
after transplantation predicts the incidence of BPAR in the first year (47). 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 
 
166 
The OPTICEPT study was a 2-year, open-label, randomized, multicenter trial comparing the 
efficacy and safety of concentration-controlled MMF dosing with a fixed-dose regimen in 
720 kidney recipients. In patients with Tacrolimus, those with higher MMF exposure had 
less rejection episodes (48). 
Similarly, a recently published substudy of the FDCC-trial in patients with delayed graft 
function disclosed significantly lower dose-corrected MPA AUC on Day 3 and Day 10 in this 
patient group (49). 
3.2 MPA-pharmacokinetics and gastro-intestinal side effects 
It is known, that side effects of MMF are causing dose reductions in approximately 60% of 
the patients leading to a cumulative and increasing risk for acute rejection (50). In addition, 
gastrointestinal (GIT) side effects affect medical adherence of the patients with consecutive 
risk for graft failure (51). In addition, dose reductions of MMF are related to increased costs, 
mainly due to frequent hospitalization of the patients (52). 
USRDS data of 3589 patients with MMF prescription and GIT complaints revealed that 
dosage reduction or discontinuation of mycophenolate mofetil in the first 6 months after 
diagnosis of GI complications was associated with significantly increased risk of graft failure 
and increased healthcare costs in adult renal transplant recipients (53). Another report from 
USRDS data of 3675 patients with gastrointestinal complications under MMF and 
subsequent dose reduction also disclosed an increased risk for graft loss after dose reduction 
or discontinuation of MMF (54).  
The enteric coated preparation of mycophenolate (EC-MPS) is attributed to a lower rate of 
gastrointestinal side effects, but in a prospective study based on patient questionnaires the 
rate of gastrointestinal side effects was nearly identical between the two formulations (55). 
In addition, a double-blind study comparing MMF and the newly developed enteric-coated 
formulation of MPA (EC-MPS) showed no advantage for either of the drugs (56). In contrast, 
a large, prospective study in more than 700 renal transplant recipients disclosed a significant 
improvement in gastrointestinal adverse events after conversion from MMF to EC-MPS (57).  
A study in patients with GIT complaints under MMF switching to EC-MPS indicates that 
converting patients with mild, moderate or severe GI complaints from MMF to EC-MPS 
significantly reduces GI-related symptom burden and improves patient functioning and 
well-being (58). 
Also in liver transplant patients results are reported that converting patients with 
gastrointestinal complaints from MMF to equimolar doses of EC-MMF leads to a reduction 
of gastrointestinal-related symptom burden and frequency of stools (59). 
There is some evidence from pharmacokinetic studies that elevated MPA exposure 
correlates with the occurrence of gastrointestinal side effects. Some authors suggest that 
gastrointestinal side effects are related to exposure of the active substance MPA (60). Others 
report, that the occurrence of possibly MMF-related side effects corresponds with MPA-
AUC and MPA concentration 30 minutes after oral dose of 1000 mg (61). Also, a 
longitudinal study in 37 patients with 357 MPA measurements revealed higher trough levels 
in patients with MMF associated side effects(62). It is known that MPA trough levels >3 
mg/l, peak levels >8.09 mg/l and MPA-AUC > 37.6 mg*h/l may lead to adverse effects (63). 
Also in 31 patients after renal transplantation higher MPA-AUC (>60 mg*h/l) was 
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associated with side effects (64). Nevertheless, in a small pharmacokinetic study with 11 
hispanic renal transplant patients treated with EC-MPS the MPA-AUC does not correlate 
with overall Gastrointestinal Symptom Rating Scale scores or subscale scores (65). 
Also, a 5-year clinical follow-up study in 100 renal allograft recipients in whom MPA 
exposure was measured at 7 days, 6 weeks, 3 months, 1, 3, and 5 years post transplantation 
using abbreviated AUC measurements reported more episodes of leucopenia and  anemia 
with MPA AUC(0-12h) ranges >60 mg/L x h(-1). However, no association between incident 
episodes of diarrhea or infection and target MPA AUC (0-12 h) ranges (66). 
4. Pharmacodynamics of MPA 
4.1 Inhibition of IMPDH-activity 
Recently, pharmacodynamic measurement of MPA was introduced into clinical practice. 
Especially with the use of reversed-phase HPLC, it is possible to monitor the 
immunosuppressive effect of MPA in its target cell population by quantifying the activity of 
IMPDH. This nonradioactive method for specific measurement of IMPDH activity in 
isolated peripheral mononuclear cells was developed by direct chromatographic 
determination of produced xanthosine 5'-monophosphate (XMP). In the canine model MPA 
in therapeutic doses leads to an 50% inhibition of IMPDH-activity (67) . Application of a 
single dose of 1 g MMF in dialysis patients resulted in a significant inhibition of IMPDH 
activity in lysed mononuclear cells. IMPDH activity is inversely correlated to MPA blood 
concentrations and the IC (50) for in vitro inhibition of IMPDH activity was about 2 to 3 
µg/l. (68). In addition, others report, that IMPDH-activity on peak concentration of MPA is 
approximately 40% and could be suppressed for 8 hours (69). In general, it is assumed, that 
IMPDH activity has a substantial interindividual, but low intraindividual variability (70). 
This was also shown in pediatric patients (71). 
In addition, in renal allograft recipients an inverse relationship between plasma MPA and 
IMPDH activity within the dose interval was demonstrated and minimum IMPDH activity 
was a median 8 % of values pre-MMF dose, coinciding with the MPA peak. Six hours post-
dose, IMPDH activity had returned to pre-dose values. Patients receiving MMF had a 4.5-
fold higher pre-dose enzyme activity than transplanted patients without MMF (72).  Long-
term treatment with mycophenolate was associated with an induction of IMPDH activity 
(73). Also a study with 12 patients over two years showed an increase of type 1 IMPDH 
mRNA during the first 3 months following transplantation and reaching its maximal level 
during acute rejection episodes, whereas type2 IMPDH mRNA was stable (74). Interestingly, 
in 30 patients transplantation and the initiation of immunosuppressive therapy was 
associated with increased IMPDH1 and decreased IMPDH2 expression. In addition, patients 
with acute rejection during follow-up demonstrated higher IMPDH2 expression in 
pretransplant CD4+ cells than nonrejecting patients (75). Later, the same group described in 
detail the MMF concentration dependent modulation of IMPDH1 expression in renal 
allograft recipients (76). 
4.2 IMPDH-activity and acute rejection 
Measurement of IMPDH activity may be useful in estimating the degree of 
immunosuppression in individual patients in addition to applied MMF dose. When 
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comparing three patients groups with MMF doses of 1.0, 1.5 and 2.0 g/d there was no 
correlation between MPA-AUC (0-12) values and MMF dose detectable.  Also, the degree of 
inhibition of IMPDH activity was comparable in the three groups, indicating considerable 
interindividual pharmacodynamic variability (77). In a cross-sectional analysis patients 
experiencing acute rejection episodes had increased IMPDH activity during rejection 
episodes (78). Additional information was gained in a genotyping study in 191 kidney 
transplant patients. There, seventeen genetic variants were identified in the IMPDH1 gene 
with allele frequencies ranging from 0.2 to 42.7%. Two single-nucleotide polymorphisms, 
rs2278293 and rs2278294, were significantly associated with the incidence of biopsy-proven 
acute rejection in the first year post-transplantation (79). A similar study in 82 japanese 
transplant recipients found no difference in the incidence of subclinical acute rejection 
between IMPDH1 rs2278293 or rs2278294 polymorphisms (p = 0.243 and 0.735, 
respectively). However, the authors report that the risk of subclinical acute rejection for 
recipients who cannot adapt in therapeutic drug monitoring (TDM) of MPA seems to be 
influenced by IMPDH1 rs2278293 polymorphism (80). Also, in patients after renal 
transplantation high pre-transplant IMPDH-activity predisposes to subsequent MPA dose-
reductions and increases the risk for acute rejection (81). 
4.3 IMPDH activity and MMF or EC-MPS  
There is some discussion about the degree of IMPDH suppression with either MMF or EC-
MPS.  In a single-center, crossover study in patients treated with MMF and EC-MPS IMPDH 
activity inversely followed MPA concentrations and was inhibited to a similar degree 
(approximately 85%) by both formulations. In addition, the calculated value for 50% IMPDH 
inhibition was identical for both drugs (16). However, when comparing the 
pharmacodynamic activity of MMF and EC-MPS a series of 260 measurements in 110 
patients disclosed lower median IMPDH activity in the EC-MPS patients than in the MMF 
patients. This was especially pronounced in patients on 1440 mg/d EC-MPS compared with 
2000 mg/d MMF (82). 
Nevertheless, for EC-MPS a recently published pharmacokinetic study in 75 de-novo kidney 
transplant recipients randomly assigning the patients either to receive EC-MPS as standard 
dose  or as intensified dose revealed in an exploratory analysis of IMPDH activity that the 
intensified regimen resulted in significantly lower IMPDH activity on day 3 after 
transplantation (83). 
There is ongoing discussion about the effect of PPI therapy on pharmacokinetics of MMF 
and EC-MPS. In a cross-sectional analysis in 153 renal transplant recipients, we measured 
IMPDH-activity before the first daily dose of MMF or EC-MPS. We could not detect any 
statistical with respect to PPI intake, type or dosing of either MMF or EC-MPS (Congress of 
the German Transplant Society, 2009).  
5. Measuring IMPDH-activity 
5.1 Sample preparation 
Peripheral blood is collected in 5ml tubes with Li-heparin as anti-coagulant and stored at 
room temperature. Heparin is superior to EDTA as anti-coagulant since it maintains cell 
viability for longer time. Within four hours after arrival of the sample to the lab, and within 
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no more than two days of collection, the peripheral mononuclear cell fraction is isolated by 
density centrifugation according to a modified protocol from Glander et al. (2001). Li-
heparinized blood (2.5ml) is mixed with an equal volume of phosphate-buffered saline 
(PBS), carefully layered on 4ml Lymphodex (InnoTrain, Germany) density gradient 
centrifugation medium in a 15ml screw-cap polypropylene tube, and centrifuged at 1200 x g 
for 15 min without brake at room temperature.  
The mononuclear cell fraction is collected from the interphase and transferred into a fresh 
15ml screw-cap tube with 5ml PBS for washing. The cells are washed only once with PBS 
since repeated washing steps might cause diffusion of mycophenolate from the cells, 
resulting in over-estimation of the residual IMPDH activity. After centrifugation at 1200 x g 
for 10 min at room temperature, the supernatant is removed quantitatively. This step is 
crucial with respect to the assay validity, since only a minute fraction of the total 
mycophenolate is contained within the cells, while the vast majority (estimated 99%) is 
present in the plasma. Any trace of the supernatant might therefore still contain 
considerable amounts of mycophenolate, hence leading to a vast underestimation of the 
residual IMPDH activity. The cell pellet is resuspended in 250µl ice-cold HPLC-grade water, 
and 125µl of the sample are transferred into each of two 2ml screw-cap vials, one designated 
as working sample, the second as back-up. The vials are deep frozen at -80°C until assayed. 
In the same way, control cells from healthy probands are prepared; these cells will be 
included in each assay as an incubation control.  
5.2 IMPDH activity assay 
The residual IMPDH activity is assayed in a cell-free system. The patient samples and 
control cells are thawed at room temperature and vigorously vortexed for 30 seconds to 
support cell lysis; insoluble cell fragments are removed by centrifugation at 4000 x g for 5 
min at room temperature in a desktop centrifuge. Cell lysate (50µl) is added to 100µl 
incubation buffer containing 1 mmol/L inosine-monophosphate (IMP) as substrate, 0.5 
mmol/L NAD as co-substrate, 72 mmol/L sodium dihydrogen-phosphate, and 180 mmol/L 
potassium chloride (pH = 7.5). After adjusting the volume to 180ml with distilled water, the 
samples are incubated at 37°C in a heating block. In presence of NAD, IMPDH converts 
inosine-monophosphate to xanthine 5’-mono-phosphate. In the subsequent high-
performance liquid chromatography (HPLC) assay, the amount of synthesized xanthine 5’-
monophosphate is determined together with the amount of AMP, which serves as an 
internal standard for normalization to the cell count. 
After exactly 2.5 hours of incubation, the reaction is stopped by adding 20µl ice-cold 4mol/L 
perchloric acid. Precipitation of denatured protein is enhanced by incubating the samples at 
-20°C for 10 min. After centrifugation at 13000 rpm for 2 min in a desktop centrifuge, 170µl 
supernatant are transferred to a test tube containing 14µl 2.5 mol/L potassium carbonate 
solution for neutralization. The exact volume of potassium carbonate, required to achieve a 
final pH between pH 6 and pH 7, has to be determined for each lot of 4 mol/L perchloric 
acid and 2.5 mol/L potassium carbonate solution. Prior to HPLC analysis, the samples are 
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5.3 HPLC chromatography 
Determination of the amounts of xanthine-monophosphate and adenosine-monophosphate 
is carried out by ion-pair reversed-phase high-performance liquid chromatography on a 
computerized isocratic HPLC system from Shimadzu (Kyoto, Japan) consisting of a system 
controller SCL-10A VP, an HPLC pump LC-10AT VP, an autoinjector SIL-10AF, a column 
oven CTO-10AS VP, and an UV-VIS detector SPD-10A VP, controlled by Shimadzu LC 
Solution data collection software.  
For the assay 6µl of the samples are loaded onto a 250 mm x 3.1 mm Prontosil 120 to 5 ODS 
AQ column (Bischoff Chromatography, Leonberg, Germany). Column oven temperature is 
set to 40°C. Chromatographic separation is achieved using a mobile phase containing 50 
mmol/L potassium-dihydrogen-phosphate, 7 mmol/L tetra-n-butyl-ammonium hydrogen 
sulfate, and 6% (v/v) methanol at a flow rate of 1 mL/min. The analytes are detected at 254-
nm wavelength. Incubation efficacy is verified by including a sample from a healthy 
volunteer as incubation control in each incubation cycle. For calibration, two standards 
containing 500 and 2500 pmol xanthin-monophosphate and adenosin-monophosphate, 
respectively, in 0.4% BSA solution are processed in several independent experiments, and 
repeatedly measured, like the patient specimen: protein denaturation with perchloric acid 
followed by neutralization with potassium carbonate. This calibration curve allows to 
deduct the amount of XMP synthesized during incubation and the amount of AMP in the 
sample. The specific IMPDH activity is then expressed as pmol XMP synthesized per 
second, which is normalized to 1 pmol of AMP [pmol XMP/(pmol AMP s)]. 
6. Summary and conclusion 
Mycophenolic-acid (MPA) is a selective, non-competitive inhibitor of Inosine-
Monophosphate-Dyhydrogenase (IMPDH) leading to the inhibition of the de-novo 
synthesis of guanosine-nucleotides. In human lymphocytes inhibition of IMPDH results in 
altered cellular proliferation with arrest in the S-phase of the cell cycle. Due to the absence of 
a salvage pathway, proliferating activated t-cells are severely affected by the inhibitory 
effects of MPA. 
In patients after renal transplantation, MPA is a well-established part of 
immunosuppressive therapy, applied either as mycophenolate-mofetil (MMF, Cellcept) or 
as mycophenolate-sodium (MPS, Myfortic). MMF is used in prophylaxis of kidney rejection 
for nearly 15 years in daily doses of 2 – 3 g/d. The enteric-coated MPS is available since a 
few years; the recommended daily dose is 1440 mg/d. Both preparations are equipotent, 
when given in equimolar doses. 
In recent years drug monitoring of MPA gained more and more attention proving its 
usefulness in clinical setting. Relevant information could be collected by measuring MPA 
drug exposure by calculating the MPA-Area under the curve (MPA-AUC) with 
pharmacokinetic modeling allowing estimating the degree of immunosuppression. 
In different clinical studies MPA-AUC target concentrations of 30 – 60 µg*h/ml were 
correlated to a low rate of rejections and less occurrence of drug induced side effects. 
Clinically important, MPA metabolism is influenced not only by the choice of 
immunosuppressive medication, but also by renal function and concomitant medication.  
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Recently pharmacodynamic measurement of MPA was introduced into clinical practice. 
Especially with the use of reversed-phase HPLC, it becomes possible to monitor the 
immunosuppressive effect of MPA in its target cell population by quantifying the activity of 
IMPDH. IMPDH activity is inversely correlated to MPA blood concentrations. Maximum 
inhibition of IMPDH activity ranges between 60% and 80% and the reported IC (50) of 
IMPDH activity corresponds to MPA blood levels of 2-3 µ/l. In renal transplant recipients, 
IMPDH shows relevant inter-individual variability. However, pre-transplant IMPDH 
activity was predictive for increased risk of rejection when additional dose reductions of 
MMF were necessary. In a cross-sectional studies better transplant function was associated 
with lower IMPDH-activity and probably the usage of EC-MPS. Pharmacokinetic and 
pharmacodynamic parameters of MPA are influenced by additional immunosuppression. In 
addition, concomitant therapy especially the use of proton-pump inhibitors affects MPA-
levels, whereas an effect of IMPDH-activity, at least in renal transplant recipients could not 
be disclosed. Therefore, it can be concluded, that pharmacokinetic and pharmacodynamic 
measurements of MPA adds relevant information to improve clinical care of renal transplant 
recipients. 
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